RecoveryResearch Phase

DSIP (Delta Sleep-Inducing Peptide)

Subcutaneous injection, Intravenous, Intranasal

Overview

A naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood of rabbits during induced sleep. DSIP modulates sleep architecture by promoting delta wave (slow-wave) sleep through interactions with the GABAergic system and hypothalamic sleep centers.

Mechanism of Action

It also exhibits stress-protective, analgesic, and neuromodulatory properties..

Research Summary & Key Findings

Clinical studies showed normalization of disturbed sleep patterns in insomnia patients without next-day sedation. Demonstrated reduction in stress-related corticotropin levels. Limited clinical data but preclinical models show consistent sleep-promoting and neuroprotective effects.

Clinical Status

Research Phase

DSIP (Delta Sleep-Inducing Peptide) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Subcutaneous injectionIntravenousIntranasal

Related Peptides in Recovery

Find a Provider

Find a verified provider who offers DSIP (Delta Sleep-Inducing Peptide) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply DSIP (Delta Sleep-Inducing Peptide).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.